Global Asthma Therapeutics Market

Asthma Therapeutics Comprehensive Study by Type (Dry Powder Inhalers, Metered Dose Inhalers, Mist Inhalers, Nebulizer), Route Of Administration (Inhalation, Oral, Parenteral), Drug Class (Anti-Inflammatory Drugs, Bronchodilators, Combination Therapy), Relief Time (Quick-Relief Medications, Long-Term Asthma Control Medications) Players and Region - Global Market Outlook to 2028

Asthma Therapeutics Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 2.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Asthma Therapeutics Market Scope
Changing lifestyles that effect the occurrences of asthma will help to boost global asthma therapeutic market. Asthma is a type of chronic disease of airways of the lungs. Categorized by several symptoms including bronchospasm, and pulmonary airway obstructions. There are various symptoms of asthma including cough, shortness of breath, wheezing and chest tightness. The symptoms can be prohibited by avoiding exposure to allergens and irritants.

According to AMA, the Global Asthma Therapeutics market is expected to see growth rate of 2.2%

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that European Players will contribute to the maximum growth of Global Asthma Therapeutics market throughout the predicted period.

AstraZeneca Plc (United Kingdom), Philips Healthcare (Netherlands), Teva Pharmaceutical Industries Ltd. (Israel), CareFusion Corporation (United States), GlaxoSmithKline Plc (United Kingdom), Sanofi-Aventis SA (France), Sunovion Pharmaceuticals, Inc. (United States), Roche Diagnostics (Switzerland), Boehringer Ingelheim GmbH (Germany) and Merck & Co., Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Novartis AG. (Switzerland).

Segmentation Overview
The study have segmented the market of Global Asthma Therapeutics market by Type (Dry Powder Inhalers, Metered Dose Inhalers, Mist Inhalers and Nebulizer) and Region with country level break-up.

On the basis of geography, the market of Asthma Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Switzerland, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Israel, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2022. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement.

Influencing Trend:
Increasing Incidences of Respiratory Diseases Coupled and Upsurging Healthcare Expenditure

Market Growth Drivers:
Growing Amount of Pollution All Over the World and Rise in the Number of Smokers

Challenges:
Lack of Patient Acquaintance with the Standard Therapies

Restraints:
Costly Medications of Asthma Therapeutics

Opportunities:
Huge Demand for Diagnostic Tools to Deliver a Reliable Diagnosis Of Asthma In Young Children and The Innovation of New Drugs

Market Leaders and their Expansionary Development Strategies
On 8th July 2021 - Royal Philips, a global leader in health technology, and Cognizant, a world-leading professional services firm, today announced a new collaboration to develop end-to-end digital health solutions that will enable healthcare organizations and life sciences companies to improve patient care and accelerate clinical trials., On 28th June 2021 - Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Bioeq AG announced that they have entered into a strategic partnership for the exclusive commercialization of Bioeq's FYB201, a biosimilar candidate to Lucentis (ranibizumab) in Europe, Canada, Israel and New Zealand. and 20th December 2018, AstraZeneca has announced that the European Commission (EC) has approved Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in a pressurized metered-dose inhaler (pMDI) as a maintenance dual bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
February 2023 New data on the Digihaler system, a US affiliate of Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd., presented at the American Academy of Allergy, Asthma and Immunology (AAAI) 2023 Annual Meeting, February 24-27 has been announced. in San Antonio, Texas. The data includes the results of the CONNECT2 clinical trial program and the actual use of smart inhaler systems by patients and healthcare professionals.
Guidelines for the Diagnosis and Management of Asthma (EPR-3) are a set of recommendations for ideal asthma management. EPR-3 provides guidance for selecting treatment based on a patient's individual needs and level of asthma control. The guidelines emphasize that while asthma can be controlled, the condition can change over time and differs among individuals and by age groups. Thus, it is important to monitor the patient's level of asthma control regularly so that treatment can be adjusted as needed.

Key Target Audience
Medical Institutes, Government Research Organizations, Private Research Organizations, Government Regulatory Bodies and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Type
  • Dry Powder Inhalers
  • Metered Dose Inhalers
  • Mist Inhalers
  • Nebulizer
By Route Of Administration
  • Inhalation
  • Oral
  • Parenteral

By Drug Class
  • Anti-Inflammatory Drugs
  • Bronchodilators
  • Combination Therapy

By Relief Time
  • Quick-Relief Medications
  • Long-Term Asthma Control Medications

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Switzerland
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Israel
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Amount of Pollution All Over the World
      • 3.2.2. Rise in the Number of Smokers
    • 3.3. Market Challenges
      • 3.3.1. Lack of Patient Acquaintance with the Standard Therapies
    • 3.4. Market Trends
      • 3.4.1. Increasing Incidences of Respiratory Diseases Coupled
      • 3.4.2. Upsurging Healthcare Expenditure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Asthma Therapeutics, by Type, Route Of Administration, Drug Class, Relief Time and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Asthma Therapeutics (Value)
      • 5.2.1. Global Asthma Therapeutics by: Type (Value)
        • 5.2.1.1. Dry Powder Inhalers
        • 5.2.1.2. Metered Dose Inhalers
        • 5.2.1.3. Mist Inhalers
        • 5.2.1.4. Nebulizer
      • 5.2.2. Global Asthma Therapeutics by: Route Of Administration (Value)
        • 5.2.2.1. Inhalation
        • 5.2.2.2. Oral
        • 5.2.2.3. Parenteral
      • 5.2.3. Global Asthma Therapeutics by: Drug Class (Value)
        • 5.2.3.1. Anti-Inflammatory Drugs
        • 5.2.3.2. Bronchodilators
        • 5.2.3.3. Combination Therapy
      • 5.2.4. Global Asthma Therapeutics by: Relief Time (Value)
        • 5.2.4.1. Quick-Relief Medications
        • 5.2.4.2. Long-Term Asthma Control Medications
      • 5.2.5. Global Asthma Therapeutics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Switzerland
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Israel
          • 5.2.5.4.3. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Asthma Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca Plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Philips Healthcare (Netherlands)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. CareFusion Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi-Aventis SA (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sunovion Pharmaceuticals, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Roche Diagnostics (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Boehringer Ingelheim GmbH (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck & Co., Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Asthma Therapeutics Sale, by Type, Route Of Administration, Drug Class, Relief Time and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Asthma Therapeutics (Value)
      • 7.2.1. Global Asthma Therapeutics by: Type (Value)
        • 7.2.1.1. Dry Powder Inhalers
        • 7.2.1.2. Metered Dose Inhalers
        • 7.2.1.3. Mist Inhalers
        • 7.2.1.4. Nebulizer
      • 7.2.2. Global Asthma Therapeutics by: Route Of Administration (Value)
        • 7.2.2.1. Inhalation
        • 7.2.2.2. Oral
        • 7.2.2.3. Parenteral
      • 7.2.3. Global Asthma Therapeutics by: Drug Class (Value)
        • 7.2.3.1. Anti-Inflammatory Drugs
        • 7.2.3.2. Bronchodilators
        • 7.2.3.3. Combination Therapy
      • 7.2.4. Global Asthma Therapeutics by: Relief Time (Value)
        • 7.2.4.1. Quick-Relief Medications
        • 7.2.4.2. Long-Term Asthma Control Medications
      • 7.2.5. Global Asthma Therapeutics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Switzerland
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Israel
          • 7.2.5.4.3. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Asthma Therapeutics: by Type(USD Million)
  • Table 2. Asthma Therapeutics Dry Powder Inhalers , by Region USD Million (2017-2022)
  • Table 3. Asthma Therapeutics Metered Dose Inhalers , by Region USD Million (2017-2022)
  • Table 4. Asthma Therapeutics Mist Inhalers , by Region USD Million (2017-2022)
  • Table 5. Asthma Therapeutics Nebulizer , by Region USD Million (2017-2022)
  • Table 6. Asthma Therapeutics: by Route Of Administration(USD Million)
  • Table 7. Asthma Therapeutics Inhalation , by Region USD Million (2017-2022)
  • Table 8. Asthma Therapeutics Oral , by Region USD Million (2017-2022)
  • Table 9. Asthma Therapeutics Parenteral , by Region USD Million (2017-2022)
  • Table 10. Asthma Therapeutics: by Drug Class(USD Million)
  • Table 11. Asthma Therapeutics Anti-Inflammatory Drugs , by Region USD Million (2017-2022)
  • Table 12. Asthma Therapeutics Bronchodilators , by Region USD Million (2017-2022)
  • Table 13. Asthma Therapeutics Combination Therapy , by Region USD Million (2017-2022)
  • Table 14. Asthma Therapeutics: by Relief Time(USD Million)
  • Table 15. Asthma Therapeutics Quick-Relief Medications , by Region USD Million (2017-2022)
  • Table 16. Asthma Therapeutics Long-Term Asthma Control Medications , by Region USD Million (2017-2022)
  • Table 17. South America Asthma Therapeutics, by Country USD Million (2017-2022)
  • Table 18. South America Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 19. South America Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 20. South America Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 21. South America Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 22. Brazil Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 23. Brazil Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 24. Brazil Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 25. Brazil Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 26. Argentina Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 27. Argentina Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 28. Argentina Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 29. Argentina Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 30. Rest of South America Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 31. Rest of South America Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 32. Rest of South America Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 33. Rest of South America Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 34. Asia Pacific Asthma Therapeutics, by Country USD Million (2017-2022)
  • Table 35. Asia Pacific Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 36. Asia Pacific Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 37. Asia Pacific Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 38. Asia Pacific Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 39. China Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 40. China Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 41. China Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 42. China Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 43. Japan Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 44. Japan Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 45. Japan Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 46. Japan Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 47. India Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 48. India Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 49. India Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 50. India Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 51. South Korea Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 52. South Korea Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 53. South Korea Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 54. South Korea Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 55. Taiwan Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 56. Taiwan Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 57. Taiwan Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 58. Taiwan Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 59. Australia Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 60. Australia Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 61. Australia Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 62. Australia Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 63. Rest of Asia-Pacific Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 67. Europe Asthma Therapeutics, by Country USD Million (2017-2022)
  • Table 68. Europe Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 69. Europe Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 70. Europe Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 71. Europe Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 72. Germany Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 73. Germany Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 74. Germany Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 75. Germany Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 76. France Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 77. France Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 78. France Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 79. France Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 80. Switzerland Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 81. Switzerland Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 82. Switzerland Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 83. Switzerland Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 84. United Kingdom Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 85. United Kingdom Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 86. United Kingdom Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 87. United Kingdom Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 88. Netherlands Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 89. Netherlands Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 90. Netherlands Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 91. Netherlands Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 92. Rest of Europe Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 93. Rest of Europe Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 94. Rest of Europe Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 95. Rest of Europe Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 96. MEA Asthma Therapeutics, by Country USD Million (2017-2022)
  • Table 97. MEA Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 98. MEA Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 99. MEA Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 100. MEA Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 101. Middle East Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 102. Middle East Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 103. Middle East Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 104. Middle East Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 105. Israel Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 106. Israel Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 107. Israel Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 108. Israel Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 109. Africa Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 110. Africa Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 111. Africa Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 112. Africa Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 113. North America Asthma Therapeutics, by Country USD Million (2017-2022)
  • Table 114. North America Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 115. North America Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 116. North America Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 117. North America Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 118. United States Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 119. United States Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 120. United States Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 121. United States Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 122. Canada Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 123. Canada Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 124. Canada Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 125. Canada Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 126. Mexico Asthma Therapeutics, by Type USD Million (2017-2022)
  • Table 127. Mexico Asthma Therapeutics, by Route Of Administration USD Million (2017-2022)
  • Table 128. Mexico Asthma Therapeutics, by Drug Class USD Million (2017-2022)
  • Table 129. Mexico Asthma Therapeutics, by Relief Time USD Million (2017-2022)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Asthma Therapeutics: by Type(USD Million)
  • Table 141. Asthma Therapeutics Dry Powder Inhalers , by Region USD Million (2023-2028)
  • Table 142. Asthma Therapeutics Metered Dose Inhalers , by Region USD Million (2023-2028)
  • Table 143. Asthma Therapeutics Mist Inhalers , by Region USD Million (2023-2028)
  • Table 144. Asthma Therapeutics Nebulizer , by Region USD Million (2023-2028)
  • Table 145. Asthma Therapeutics: by Route Of Administration(USD Million)
  • Table 146. Asthma Therapeutics Inhalation , by Region USD Million (2023-2028)
  • Table 147. Asthma Therapeutics Oral , by Region USD Million (2023-2028)
  • Table 148. Asthma Therapeutics Parenteral , by Region USD Million (2023-2028)
  • Table 149. Asthma Therapeutics: by Drug Class(USD Million)
  • Table 150. Asthma Therapeutics Anti-Inflammatory Drugs , by Region USD Million (2023-2028)
  • Table 151. Asthma Therapeutics Bronchodilators , by Region USD Million (2023-2028)
  • Table 152. Asthma Therapeutics Combination Therapy , by Region USD Million (2023-2028)
  • Table 153. Asthma Therapeutics: by Relief Time(USD Million)
  • Table 154. Asthma Therapeutics Quick-Relief Medications , by Region USD Million (2023-2028)
  • Table 155. Asthma Therapeutics Long-Term Asthma Control Medications , by Region USD Million (2023-2028)
  • Table 156. South America Asthma Therapeutics, by Country USD Million (2023-2028)
  • Table 157. South America Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 158. South America Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 159. South America Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 160. South America Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 161. Brazil Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 162. Brazil Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 163. Brazil Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 164. Brazil Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 165. Argentina Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 166. Argentina Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 167. Argentina Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 168. Argentina Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 169. Rest of South America Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 170. Rest of South America Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 171. Rest of South America Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 172. Rest of South America Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 173. Asia Pacific Asthma Therapeutics, by Country USD Million (2023-2028)
  • Table 174. Asia Pacific Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 175. Asia Pacific Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 176. Asia Pacific Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 177. Asia Pacific Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 178. China Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 179. China Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 180. China Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 181. China Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 182. Japan Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 183. Japan Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 184. Japan Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 185. Japan Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 186. India Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 187. India Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 188. India Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 189. India Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 190. South Korea Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 191. South Korea Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 192. South Korea Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 193. South Korea Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 194. Taiwan Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 195. Taiwan Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 196. Taiwan Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 197. Taiwan Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 198. Australia Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 199. Australia Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 200. Australia Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 201. Australia Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 202. Rest of Asia-Pacific Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 203. Rest of Asia-Pacific Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 204. Rest of Asia-Pacific Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 205. Rest of Asia-Pacific Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 206. Europe Asthma Therapeutics, by Country USD Million (2023-2028)
  • Table 207. Europe Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 208. Europe Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 209. Europe Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 210. Europe Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 211. Germany Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 212. Germany Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 213. Germany Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 214. Germany Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 215. France Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 216. France Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 217. France Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 218. France Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 219. Switzerland Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 220. Switzerland Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 221. Switzerland Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 222. Switzerland Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 223. United Kingdom Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 224. United Kingdom Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 225. United Kingdom Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 226. United Kingdom Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 227. Netherlands Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 228. Netherlands Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 229. Netherlands Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 230. Netherlands Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 231. Rest of Europe Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 232. Rest of Europe Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 233. Rest of Europe Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 234. Rest of Europe Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 235. MEA Asthma Therapeutics, by Country USD Million (2023-2028)
  • Table 236. MEA Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 237. MEA Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 238. MEA Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 239. MEA Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 240. Middle East Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 241. Middle East Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 242. Middle East Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 243. Middle East Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 244. Israel Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 245. Israel Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 246. Israel Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 247. Israel Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 248. Africa Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 249. Africa Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 250. Africa Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 251. Africa Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 252. North America Asthma Therapeutics, by Country USD Million (2023-2028)
  • Table 253. North America Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 254. North America Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 255. North America Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 256. North America Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 257. United States Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 258. United States Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 259. United States Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 260. United States Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 261. Canada Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 262. Canada Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 263. Canada Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 264. Canada Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 265. Mexico Asthma Therapeutics, by Type USD Million (2023-2028)
  • Table 266. Mexico Asthma Therapeutics, by Route Of Administration USD Million (2023-2028)
  • Table 267. Mexico Asthma Therapeutics, by Drug Class USD Million (2023-2028)
  • Table 268. Mexico Asthma Therapeutics, by Relief Time USD Million (2023-2028)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Asthma Therapeutics: by Type USD Million (2017-2022)
  • Figure 5. Global Asthma Therapeutics: by Route Of Administration USD Million (2017-2022)
  • Figure 6. Global Asthma Therapeutics: by Drug Class USD Million (2017-2022)
  • Figure 7. Global Asthma Therapeutics: by Relief Time USD Million (2017-2022)
  • Figure 8. South America Asthma Therapeutics Share (%), by Country
  • Figure 9. Asia Pacific Asthma Therapeutics Share (%), by Country
  • Figure 10. Europe Asthma Therapeutics Share (%), by Country
  • Figure 11. MEA Asthma Therapeutics Share (%), by Country
  • Figure 12. North America Asthma Therapeutics Share (%), by Country
  • Figure 13. Global Asthma Therapeutics share by Players 2022 (%)
  • Figure 14. Global Asthma Therapeutics share by Players (Top 3) 2022(%)
  • Figure 15. Global Asthma Therapeutics share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. AstraZeneca Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. AstraZeneca Plc (United Kingdom) Revenue: by Geography 2022
  • Figure 19. Philips Healthcare (Netherlands) Revenue, Net Income and Gross profit
  • Figure 20. Philips Healthcare (Netherlands) Revenue: by Geography 2022
  • Figure 21. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 22. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2022
  • Figure 23. CareFusion Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 24. CareFusion Corporation (United States) Revenue: by Geography 2022
  • Figure 25. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2022
  • Figure 27. Sanofi-Aventis SA (France) Revenue, Net Income and Gross profit
  • Figure 28. Sanofi-Aventis SA (France) Revenue: by Geography 2022
  • Figure 29. Sunovion Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Sunovion Pharmaceuticals, Inc. (United States) Revenue: by Geography 2022
  • Figure 31. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Roche Diagnostics (Switzerland) Revenue: by Geography 2022
  • Figure 33. Boehringer Ingelheim GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Boehringer Ingelheim GmbH (Germany) Revenue: by Geography 2022
  • Figure 35. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 37. Global Asthma Therapeutics: by Type USD Million (2023-2028)
  • Figure 38. Global Asthma Therapeutics: by Route Of Administration USD Million (2023-2028)
  • Figure 39. Global Asthma Therapeutics: by Drug Class USD Million (2023-2028)
  • Figure 40. Global Asthma Therapeutics: by Relief Time USD Million (2023-2028)
  • Figure 41. South America Asthma Therapeutics Share (%), by Country
  • Figure 42. Asia Pacific Asthma Therapeutics Share (%), by Country
  • Figure 43. Europe Asthma Therapeutics Share (%), by Country
  • Figure 44. MEA Asthma Therapeutics Share (%), by Country
  • Figure 45. North America Asthma Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca Plc (United Kingdom)
  • Philips Healthcare (Netherlands)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • CareFusion Corporation (United States)
  • GlaxoSmithKline Plc (United Kingdom)
  • Sanofi-Aventis SA (France)
  • Sunovion Pharmaceuticals, Inc. (United States)
  • Roche Diagnostics (Switzerland)
  • Boehringer Ingelheim GmbH (Germany)
  • Merck & Co., Inc. (United States)
Additional players considered in the study are as follows:
Novartis AG. (Switzerland)
Select User Access Type

Key Highlights of Report


Apr 2023 224 Pages 66 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Asthma Therapeutics Market Quantitative research analysis
Global Asthma Therapeutics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Asthma Therapeutics study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Asthma Therapeutics Market is gaining popularity and expected to see strong valuation by 2028 .
According to AMA, the Global Asthma Therapeutics market is expected to see growth rate of xx%.
The Asthma Therapeutics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Asthma Therapeutics Market Report?

Have a Query? Click Here

Other Related Reports

Bacterial Vaginosis Drugs Comprehensive Study by Type (Oral, Topical), Application (Pelvic Inflammatory Disease, Preterm Delivery of Infants, Urinary Tract Infection, Sexually Transmitted Diseases (S...
$ 3750
Sickle Cell Disease Treatment Comprehensive Study by Type (Sickle Cell Anemia, Sickle Beta Thalassemia, Sickle Hemoglobin C Disease), Application (Hospitals, Clinics, Others), Medication (Antimetabol...
$ 3650
Exosome Diagnostics and Therapeutics Comprehensive Study by Type (Diagnostic, Therapeutic), Application (Cancer Institute, Hospital, Diagnostic Center, Others), Components (Instrument, Reagent, Softw...
$ 3750
Gonorrhea Testing Comprehensive Study by Test (Nucleic Acid Amplification (NAA), Gram Stain, Enzyme-linked immunosorbent assay (ELISA), Gonorrhea Culture, Rapid test), Sample (Blood, Lymph fluid, Uri...
$ 3450
Microwave Therapeutic Instruments Comprehensive Study by Type (Monopolar, Bipolar), Application (Arthritis, Back Pain, Fibromyalgia, Muscle Spasms, Myositis, Neuralgia, Sprains And Strains, Tenosynov...
$ 3650
Diagnostic Technology Comprehensive Study by Type (Immunoassay/Immunochemistry, Clinical Chemistry, Molecular Diagnostics, Microbiology, Hematology, Coagulation and Hemostasis, Urinalysis, Other IVD ...
$ 3750